Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.540 -0.160 (-5.93%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy ↗
-Clinical Data Due Next Week at ASH- 
Via Benzinga
Analyst Ratings for Editas Medicine ↗
 
Via Benzinga
News headline image
2 Beaten-Down Stocks to Watch Closely Next Year ↗
These biotechs could skyrocket in 2023, but only if they can execute their plans. 
Via The Motley Fool
News headline image
Editas Medicine Touts Positive Safety, Efficacy Data From Two Sickle Cell Disease Patients ↗
 
Via Benzinga
News headline image
Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Why Shares of Editas Medicine Dropped 15.5% in November ↗
The biotech's shares plummeted after it paused a key clinical trial. 
Via The Motley Fool
News headline image
Why Editas Medicine's Shares Are Falling Thursday ↗
The company shelved a clinical trial for one of its lead therapies. 
Via The Motley Fool
News headline image
Editas Medicine: Q3 Earnings Insights ↗
Editas Medicine (NASDAQ:EDIT) reported its Q3 earnings results on Wednesday, November 2, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Where Will Editas Medicine Be in 1 Year? ↗
The company could continue lagging the market for a while. 
Via The Motley Fool
News headline image
Gene Editing Stock's Prospects Cut In Half By Analyst, Citing Limited Value In Retina Treatment ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Palo Alto To Surge Around 38%? Plus This Analyst Predicts $65 For Helmerich & Payne ↗
Barclays raised the price target on Palo Alto Networks, Inc. (NASDAQ: PANW) from $200 to $215. Barclays analyst Saket Kalia maintained an Overweight rating on the stock. Palo Alto Networks shares fell... 
Via Benzinga
News headline image
Intuit To $490? Here Are 5 Other Price Target Changes For Friday ↗
Barclays cut Intuit Inc. (NASDAQ: INTU) price target from $502 to $490. . Barclays analyst Raimo Lenschow maintained an Overweight rating on the stock. Intuit shares fell 3% to close at $381.88 on... 
Via Benzinga
News headline image
Gap To Rally 18%? Plus This Analyst Slashes PT On Super League Gaming By 50% ↗
  Telsey Advisory Group boosted the price target on The Gap, Inc. (NYSE: GPS) from $10 to $15. Gap shares rose 5.6% to close at $12.71 on Thursday. 
Via Benzinga
News headline image
Nasdaq Down 60 Points; Alibaba Posts Upbeat Q2 Earnings ↗
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 60 points on Thursday. 
Via Benzinga
News headline image
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday ↗
Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday. 
Via Benzinga
News headline image
Why Elevate Credit Shares Are Trading Higher By Over 71%? Here Are 43 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Elevate Credit, Inc. (NYSE: ELVT) shares surged 71.2% to $1.8150 after the company agreed to be acquired by Park Cities Asset Management in an all-cash transaction at an implied value of $67... 
Via Benzinga
News headline image
Citing Small Population, Editas Medicine Pauses Work On Gene Therapy Trial For Genetic Eye Disorder ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
S&P 500 Down 1%; Crude Oil Drops Sharply ↗
U.S. stocks traded lower midway through trading, with the S&P 500 dropping around 1% on Thursday. 
Via Benzinga
News headline image
BrightView Holdings, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday ↗
U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
What 5 Analyst Ratings Have To Say About Editas Medicine ↗
Over the past 3 months, 5 analysts have published their opinion on Editas Medicine (NASDAQ:EDIT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
News headline image
Editas Medicine Announces Third Quarter 2022 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing ↗
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema. 
Via Investor's Business Daily
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.